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Abstract
BACKGROUND—Quantifying risk of advanced proximal colorectal neoplasia might allow
tailoring of colorectal cancer screening, with colonoscopy for those at high risk, and less invasive
screening for very low-risk persons.
METHODS—We analyzed findings from 10,124 consecutive adults age ≥ 50 years who
underwent screening colonoscopy to the cecum between September 1995 and August 2008. We
quantified the risk of advanced neoplasia (tubular adenoma ≥ 1 cm; a polyp with villous histology
or high-grade dysplasia; or adenocarcinoma) both proximally (cecum to splenic flexure) and
distally (descending colon to anus). Prevalence of advanced proximal neoplasia was quantified by
age, gender and distal findings.
RESULTS—Mean (s.d.) age was 57.5 (6.0) years; 44% were women; 7835 (77%) had no
neoplasia, and 1856 (18%) had one or more non-advanced adenomas. Overall, 433 subjects (4.3%)
had advanced neoplasia (267 distally; 196 proximally; 30 both), 33 (0.33%) of which were
adenocarcinoma (18 distal, 15 proximal). Risk of advanced proximal neoplasia increased with age
decade (1.13%, 2.00%, and 5.26%, respectively; P=0.001) and was higher in men (relative risk
[RR] =1.91; CI, 1.32–2.77). In women younger than 70 years, risk was 1.1% overall (vs. 2.2% in
men; RR=1.98; CI, 1.42–2.76) and was 0.86% in those with no distal neoplasia (vs. 1.54% in men;
RR=1.81; CI, 1.20–2.74).
CONCLUSION—Risk of advanced proximal neoplasia is a function of age and gender. Women
younger than age 70 have a very low risk, particularly those with no distal adenoma.
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Sigmoidoscopy with or without occult blood testing may be sufficient and even preferable for
screening these subgroups.
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Cancer screening; colonoscopy; colorectal cancer; colorectal neoplasm
INTRODUCTION
Colorectal cancer is the third most common cancer in adults in the U.S. and U.K. and the
leading cause of cancer death among non-smokers.1,2 Because of its disease burden and
natural history, colorectal cancer lends itself well to screening. Several guideline
organizations endorse colorectal cancer screening with any of several tests and strategies,
and screening rates are increasing among U.S. adults.3–5
Although several options are endorsed,3–6 colonoscopic screening is the predominant mode
of screening in the U.S.7 While colonoscopy reduces colorectal cancer incidence8,9 and is
cost-effective, 10–12 it requires considerable provider and financial resources.13,14 At the
same time, use of sigmoidoscopy screening has dramatically decreased in the U.S.,15,16
despite its being considered an option by major guideline organizations.
Since nearly 80% of persons who undergo screening colonoscopy will have no neoplasia,8
the effectiveness of sigmoidoscopy relative to colonoscopy or to fecal occult blood testing
(FOBT) might be clarified if there were a quantitative framework from which to estimate
risk for important neoplasia. Better understanding of individual patient risk might allow
colorectal cancer screening to be tailored based on risk.
In previous work, we used age, sex, and distal colorectal findings to identify a subgroup at
very low-risk for advanced proximal neoplasia.17 That subgroup included men and women
aged 50–54 years with no distal polyps, women aged 50–54 years with only distal
hyperplastic polyps, and women aged 55–59 with no distal polyps. In this paper, we identify
a larger, more homogeneous subgroup of persons - women younger than age 70 - with a
very low risk for advanced proximal neoplasia, a group for which sigmoidoscopy with or




This is a retrospective analysis of cross-sectional data from consecutive asymptomatic adults
≥ 50 years who underwent complete, first-time, screening colonoscopy between September
1995 and August 2008. Results up to June 2001 have been reported previously.17 The study
was approved by the Institutional Review Board of Indiana University at Indianapolis.
Screening program and eligible population
The study population is derived from two company-based colorectal cancer prevention
programs: Eli Lilly and Company, which began in 1995, and Marathon Oil Company, which
began in 2003. Both companies provide screening colonoscopy as a heath benefit to
employees, retirees and their dependents. The potentially eligible sample of employees and
retirees from which the study cohort has been previously described as 32% female, 90%
Caucasian, middle to upper-middle class in socioeconomic status.(17) The procedures for
patient enrollment have been described previously.17,18
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Study procedures and definitions
The location and size of all polyps and other lesions were determined prior to removal.
Methods for assessing location and size were chosen by the endoscopist. Distal location
included the descending colon, sigmoid colon, and rectum. All other locations were
considered “proximal.” Colonic segments with more than one polyp were categorized
according to the most advanced polyp. Distal findings were simulated from colonoscopy
reports rather than based on actual sigmoidoscopy.
Pathologic specimens were examined by one of three board-certified pathologists, who
classified polyps according to World Health Organization criteria.19 Histological
characteristics of polyps were reported as normal mucosa, hyperplastic, serrated, tubular,
tubulovillous or villous. An advanced neoplasm was defined as a tubular or serrated
adenoma ≥ 1 cm or any polyp with villous histology, high-grade dysplasia, or
adenocarcinoma. Lipomas, lymphoid aggregates, and non-specific findings were considered
normal findings.
Statistical analysis
Descriptive statistics were used for basic demographic features and the prevalence of each
category of findings. Using simple proportions and exact 95% confidence intervals, we
calculated the prevalence (or absolute risk) of advanced neoplasia anywhere, distally, and
proximally. We also calculated the prevalence of advanced proximal neoplasia according to
the most advanced distal finding, and according to gender and age decade (ages 50–59, 60–
69, and 70 and older). For each age group, gender, and for certain subgroups of distal
findings, we report the number of persons needed to be screened to detect one advanced
proximal neoplasm (most of which are advanced adenomas) and one proximal
adenocarcinoma.20 Data were managed with Microsoft Excel, version 11 (Microsoft). All
analyses were performed using SPSS software, version 16.0. Exact methods were used to
calculate 95% confidence limits for all proportions. A P-value less than 0.05 was considered
statistically significant.
Role of the funding source
The funding source had no role in the design, data collection, analysis or decision to submit
the paper for publication.
RESULTS
Between September 1995 and August 2008, 10,124 persons aged ≥ 50 years underwent
complete colonoscopic screening to the cecum. The cohort had a mean (+/− SD) age of 57.5
(6.0) years and was comprised of 44% women (N=4454; mean age 57.4 (6.1) years). The
mean age of the 5,670 men was 57.5 (6.0) years.
Table 1 shows the most advanced finding anywhere in the colon and rectum. Just over 77%
of patients had no neoplasia; this included 13.5% with hyperplastic polyps. Eighteen percent
had non-advanced neoplasia, while 4.3% had advanced neoplasia, 62% of which was located
distal to the splenic flexure. A total of 33 cancers (0.33%) were detected: 19 (0.34%) among
5,670 men and 14 (0.31%) among 4,454 women. Eighteen patients (10 men, 8 women) had
a distal cancer. Of the 15 patients with proximal cancers, three (20%) had associated distal
neoplasia (2 advanced, 1 non-advanced), 4 had distal hyperplastic polyps, and 8 had no
distal polyp of any kind. (Table 2)
The prevalence of advanced neoplasia by location, age decade, and gender is shown in Table
2. Risk of any advanced neoplasia increased with age decade for both men and women
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(P<0.001) and was higher in men for each decade. However, when considered by location,
the risk of advanced neoplasia – both proximal and distal – increased by age decade for men
only. Among women, the risk of advanced distal neoplasia was no different by age decade,
while the risk of advanced proximal neoplasia was higher in women aged ≥ 70 years
compared with women < 70 years (P=0.001).
Table 3 shows the prevalence of advanced proximal neoplasia based on the most advanced
distal finding. Among persons with distal hyperplastic polyps, the risk of advanced proximal
neoplasia was 1.61% (95% CI, 0.98–2.47%), which was not statistically different from
persons with no distal polyps, in whom the risk was 1.50% (95% CI, 1.24–1.80%), for a
relative risk (RR) of 1.07 (CI, 0.67–1.71). The lack of a difference in risk for advanced
proximal neoplasia was present for both men (1.99% for no distal polyps versus 1.93% for
distal hyperplastic polyps) and women (0.95% versus 1.07%). Among those with distal
hyperplastic polyps, the risk for advanced proximal neoplasia was not statistically different
between men and women (1.93% versus 1.07%; RR=1.80; CI, 0.69–4.76). However, among
those with no distal polyps, the risk for advanced proximal neoplasia was greater in men
(RR=2.10; CI, 1.41–3.12).
The presence of distal neoplasia increased the risk for advanced proximal neolasia, and was
3.14% for persons with one or more non-advanced distal adenomas and 11.2% for those
with advanced distal neoplasia, with respective RRs of 2.09 (CI, 1.42–3.07) and 7.49 (CI,
5.09–10.90) compared to persons with no distal neoplasia (Table 3). For both categories of
distal findings, there was no difference in the risk for advanced proximal neoplasia between
men and women. Risk of advanced proximal neoplasia in those with one or more non-
advanced distal tubular adenoma was 3.1% overall, and did not differ statistically between
men and women (3.4% vs. 2.7%; P=0.5) or between 50–59 and 60–69 year olds (2.2% vs.
3.5%; P=0.3), but was higher in persons age 70 and older (13.5%).
Absolute risks of advanced proximal neoplasia by age group and sex, both overall and
among those with no distal neoplasia, are shown in Table 4. The risk of advanced proximal
neoplasia increased across the three age categories (P<0.009 for all groups). Among men
and women with no distal neoplasia, men had nearly twice the risk of advanced proximal
neoplasia (RR=1.91; CI, 1.32–2.77). Women in the 50–59 and 60–69 year old age groups
had a very low risk for advanced proximal neoplasia, particularly those with no distal
neoplasia, in which the risks were 0.85% and 0.88%, respectively (Table 4), and 0.86%
overall. For men under age 70 with no distal neoplasia, the risk was 1.54% (RR=1.81 for
men vs. women; CI, 1.20–2.74). Based on the risks of advanced proximal neoplasia for these
four subgroups, Table 5 shows the numbers of persons who would need to be screened with
colonoscopy to detect one person with it. For persons age ≥ 70 years and for men ages 60–
69 years old, the yield of colonoscopy was high, with numbers needed to screen ranging
from 11 to 35. For women under age 70 and for men with no distal neoplasia, the yield of
colonoscopy was lower, with numbers needed to screen between 89 and 93. Women under
age 70 with no distal neoplasia had the lowest yield, with numbers needed to screen of 114
to 118.
The number of patients needed to screen with colonoscopy to detect one proximal cancer
were much higher than for an advanced proximal neoplasm. Among women younger than
70 years, the number needed to screen to detect one proximal cancer was 2,120 (CI, 588 to
10,000) overall and 1,926 (CI, 526–10,000) among those with no distal neoplasia. In
particular, among women 50 to 59 years old, the number needed to screen was 3,221 (CI,
588 - ∞) overall, and was 2,500 (CI, 455 - ∞) among those with no distal polyps,
suggesting a very low yield of colonoscopy for proximal cancer in the absence of a distal
adenoma. For women 60–69 years old, the number needed to screen to detect one proximal
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cancer was 1019 (CI, 182 - ∞). Among men < 70 years with no distal neoplasia, the number
needed to screen to detect one proximal cancer was 921 (CI, 400–2500), and was 853 (CI,
333–3333) overall in men < age 60.
DISCUSSION
Our findings support and extend previous findings regarding the relationships between
advanced proximal neoplasia and age, gender, and distal colorectal findings.17,18,21–25
Consistent with previous studies, this study shows that distal adenomas, but not distal
hyperplastic polyps, are associated with increased risk for advanced proximal
neoplasia.21,23,24,26,27 Further, we have identified at least one large, clinically-important
subgroup with very low risk for this finding: women younger than 70 years old who have no
distal adenomas. The yield of colonoscopy for advanced neoplasia beyond what
sigmoidoscopy would reveal is very low for women younger than age 70; it is extremely low
when the outcome is a proximal cancer. Considered together, the findings provide a basis for
tailoring the use of screening colonoscopy and, specifically, for considering not using it
solely or routinely as a primary screening test for women under age 60 and perhaps for
women under age 70. While we found nearly identical risk estimates for advanced proximal
neoplasia between women 50–59 years of age and those 60–69 years of age, the number of
women in the 60–69 age group was small relative to the 50–59 age group, and our findings
among the older age group require further study and larger numbers to validate the findings.
Further, cost-effectiveness analysis would be useful to explicitly quantify benefits and harms
among tailored screening strategies for these groups, and is beyond the scope of this report.
Adding a sensitive FOBT 282930 to sigmoidoscopy would mitigate some of the difference in
detection of advanced proximal neoplasia between sigmoidoscopy and colonoscopy, as
suggested in some quantitative analyses. 11,31,32
The concept of tailoring screening intensity based on risk is not new. Colorectal cancer
screening is tailored to be more intensive for high-risk subgroups (e.g., familial
adenomatous polyposis, hereditary non-polyposis CRC syndromes), and for persons with a
first-degree relative with colorectal cancer.4,5 In a parallel fashion, improved knowledge
about subgroups with a particularly low risk for colorectal cancer might allow more
effective tailoring of screening: those at very low-risk could be screened less invasively or
perhaps later than age 50. Such a scenario has appeal in an era of cost containment;
moreover, after a quantitative consideration of marginal risk vs. marginal benefit, it may
simply make sense to many physicians and patients.
The risk difference in the low-risk group is parallel to the magnitude currently used to make
screening decisions when there is a family history of colorectal cancer. Based on relative
risks that are elevated 2-to-3-fold in persons with a positive family history,4,5 we begin
screening sooner or recommend more invasive testing. In this study, women < age 70 had
both a very low absolute risk of advanced neoplasia (with higher numbers needed to screen)
and a relative risk that was roughly half that of similarly-aged men. Instead of tailoring for
increased risk (as with family history), we might consider tailoring for persons at lower risk,
and screen them either less invasively, later, or both.
Several features could be considered candidate risk factors for tailoring colorectal cancer
screening. Among demographic features, gender is particularly worthy of consideration.
Epidemiological and clinical data indicate that the age-adjusted risk for colorectal cancer in
men is nearly twice that for women.33–35 Several studies have found that male gender is an
independent risk factor for both colorectal cancer and for adenomatous polyps.18,21,25,36 A
systematic review of 17 screening studies and more than 924,000 persons found that men
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have a pooled relative risk for advanced neoplasia of 1.83 (CI, 1.69–1.97) that is present in
all age groups.36
Our findings in women differ from those of others,37 which found a higher prevalence of
advanced neoplasia (4.6% versus 2.6% in the current study) and a higher proportion of
proximal lesions in 1,463 women from 4 military medical centers. The prevalence of
advanced neoplasia was numerically higher in this other study for each age group,
suggesting that factors other than age (such as family history of colorectal cancer, cigarette
smoking, and body mass index) might account for the differences in risk. The reason for the
difference in distribution of advanced adenomas is uncertain. Additional data in women
based on these risk factors would be useful to understand how each factor affects the
prevalence of advanced neoplasia.
Another candidate feature for tailoring is distal colorectal findings. An extensive literature
supports a higher risk of advanced neoplasia in the proximal colon when distal neoplasia is
present, with the magnitude of risk directly related to the degree or severity of distal
neoplasia.18,21,23–26,38 Findings from this study provide further support for this literature
and for using distal findings along with other factors to estimate the risk for APN.
Use of sigmoidoscopy in the U.S. has declined for several reasons, including a lack of
training and inadequate reimbursement7,39 + Lewis 1999; however, a case can be made to
increase its use and to address the issues of training and reimbursement. First, quantitative
analyses suggest that it is an acceptable option by itself.11,31 Second, analyses done by the
U. S. Preventive Services Task Force and Institute of Medicine show that when
sigmoidoscopy is combined with guaiac-based FOBT in a program of screening, it may be
as effective or more effective than screening colonoscopy because it detects fast-growing
lesions that occur between colonoscopies.11,12,40,41 The combination of sigmoidoscopy
every 5 years with newer high sensitivity FOBT28,29,42,43 annually may provide even more
benefit in a screening program44 by detecting fast growing lesions and those missed by
colonoscopy. Third, a screening strategy of once-only sigmoidoscopy recently has been
shown to reduce incidence and mortality from left-sided colorectal cancer for at least 10
years,45,46 suggesting that such an approach is worth considering. Last, if colonoscopy has
substantially decreased effectiveness in the right colon as several but not all studies
suggest,47,4849,50 then the marginal gain from colonoscopy compared to sigmoidoscopy may
be negligible. The question of marginal effectiveness of colonoscopy over sigmoidoscopy
was addressed in a population-based study in which the relative effectiveness of
sigmoidoscopy compared with colonoscopy was 76% if sigmoidoscopy reached the junction
of the descending colon and sigmoid colon, and 83% if sigmoidoscopy reached the splenic
flexure.51 Our data help identify a subgroup with very low risk of APN neoplasia; these data
may be useful in selecting optimal screening strategies that balance benefits and harms.
This study has limitations that require comment. Distal findings were not based on an initial
examination with sigmoidoscopy, but rather, were simulated from colonoscopy. This
analysis assumes that a sigmoidoscope would reach the proximal descending colon, an
assumption that may be overly optimistic, particularly among non-specialists who do not
perform the procedure on a regular basis. We were unable to examine the effect of other
variables that might further help stratify risk for advanced neoplasia (such as body mass
index and cigarette smoking) because these factors were not routinely collected. Perhaps the
most important limitation is the uncertain clinical importance of the advanced adenoma,
which comprises most of advanced neoplasia. As we have discussed before,17,18 the natural
history of “advanced adenoma” is not clear. In deciding about intervention, behavior, not
appearance, is what counts.52,53 The lack of data on both growth rates of advanced
adenomas and factors affecting growth preclude knowing how to optimize strategies for
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colorectal cancer screening and surveillance. Finally, while the results may not generalize
well beyond Caucasian persons who are willing to undergo screening colonoscopy, a recent
study of screening colonoscopy showed similar rates of neoplasia among Caucasians,
Hispanics, and African-Americans.(Levitsky 2011)
In conclusion, the findings from more than 10,000 index screening colonoscopies show that
the risk of APN differs based on age and gender, suggesting that use of screening
colonoscopy could be tailored based on risk. In women under age 70, the risk for APN was
very low, especially in those with no distal adenoma, while the risk of a proximal cancer
was extremely low. These findings may be useful for tailoring CRC screening. In women
under age 60 or 70, consideration should be given to whether sigmoidoscopy with or without
a sensitive FOBT is sufficient screening. Further consideration of tailoring requires
independent validation of our findings and an explicit quantitative assessment of its
incremental benefits, risks, and cost.
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Table 1
Most advanced finding present on screening colonoscopy
Finding N Percent
No neoplasia 7,835 77%
 Hyperplastic polyps 1,367 13.5%
≥ 1 tubular adenoma < 1 cm 1,856 18%
Advanced neoplasia* 433 4.3%
Adenocarcinoma 33 0.33%
*
62% of advanced neoplasia was distal to the splenic fixture
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Table 3
Risk of advanced proximal neoplasia (APN) based on distal findings
Distal Finding Total N APN N Risk of APN % (95% CI) Relative Risk (95% CI)
No polyp 7594 114 1.50 (1.24–1.80) 1.0
Hyperplastic polyp 1244 20 1.61 (0.98–2.47) 1.07 (0.67–1.71)
Tubular adenoma(s) < 1 cm 1019 32 3.14 (2.16–4.40) 2.09 (1.42–3.07)
Advanced neoplasia 267 30 11.2 (7.71–15.7) 7.49 (5.09–10.90)
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Table 4
Absolute risk of advanced proximal neoplasia by age, sex, and distal findings
Group
Number with advanced proximal neoplasia/total N (%)
Age 50 –59 Age 60–69 Age ≥ 70
All men 1.75% (70/3999) 3.42% (49/1433) 8.82% (21/238)
Men, no distal neoplasia 1.38% (47/3413) 2.85% (34/1194) 7.61% (14/184)
All women 1.11% (36/3221) 1.08% (11/1019) 4.21% (9/214)
Women, no distal neoplasia 0.85% (25/2942) 0.88% (8/909) 3.06% (6/196)
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Table 5
Number needed to screen to detect 1 person with advanced proximal neoplasia
Group Ages 50 –59 Ages 60–69 Ages ≥ 70
All men 57 (45–73) 29 (22–39) 11 (8–18)
Men, no distal neoplasia 73 (55–99) 35 (25–51) 13 (8–24)
All women 89 (65–128) 93 (52–185) 24 (13–52)
Women, no distal neoplasia 118 (80–182) 114 (58–263) 33 (5–88)
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